Rizatriptan - Revision history

MDElliottMD: parser-claude: Rizatriptan MedTemplate refill, Top 300 stub upgrade

2026-05-23T07:22:13Z

parser-claude: Rizatriptan MedTemplate refill, Top 300 stub upgrade

← Older revision		Revision as of 07:22, 23 May 2026
Line 1:		Line 1:
	{{MedTemplate		{{MedTemplate
	\| generic = Rizatriptan		\| generic = Rizatriptan (benzoate)
	\| brand = Maxalt		\| brand = Maxalt (tablet), Maxalt-MLT (orally disintegrating tablet)
	\| structure =		\| structure =
	\| classes = Triptan~~, Migraine medicine~~		\| classes = [[:Category:Triptans\|Triptan (5-HT1B/1D agonist)]], [[:Category:Antimigraine medicines\|Antimigraine medicine]], [[:Category:Analgesics\|Analgesic]]
	~~\| mechanism =~~ 5-HT1B/1D agonist		\| uses = <vote slug="acute-migraine-use">Acute migraine with or without aura (FDA; adult and pediatric ages 6+)</vote>
	\| uses =		\| starting_dose = 5-10 mg PO at migraine onset; may repeat after 2 hours, maximum 30 mg/24 hours
	\| starting_dose =		\| preparations = Tablets 5, 10 mg; ODT (Maxalt-MLT) 5, 10 mg
	\| preparations =		\| fda_max = 30 mg/24 hours
	\| fda_max =		\| pill_id =
	\| routes =		\| routes = Oral
	\| onset =		\| onset = 30 minutes for migraine relief
	\| duration =		\| duration = 4-6 hours; headache recurrence is common
	\| halflife =		\| halflife = 2-3 hours<ref name="maxalt-label">FDA Prescribing Information, Maxalt (rizatriptan benzoate), Merck, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020864s022,020865s024lbl.pdf</ref>
	~~\| bioavailability =~~		\| bioavailability = ~45% (oral; substantially higher than sumatriptan's ~14%)<ref name="maxalt-label" />
	~~\| pregnancy~~ =		\| pregnancy = Limited human data; pregnancy registry data have been broadly reassuring across the triptan class.{{citation needed}}
	~~\| legal~~ =		\| legal = [[USLegal:Prescription only\|Rx-only]] in US
	\| ~~intro =~~		\| mechanism = <vote slug="rizatriptan-mech-claim">Selective 5-HT1B and 5-HT1D receptor agonist (the triptan-class signature). Compared to sumatriptan, oral bioavailability is substantially higher (~45% vs ~14%) and onset is faster, with similar headache-recurrence rates. The 5-HT1B effect produces cranial vasoconstriction reversing the neurogenic vasodilation of migraine; the 5-HT1D effect inhibits CGRP release at trigeminal nerve terminals.</vote> '''Propranolol substantially raises rizatriptan exposure''' (~70% increase) via MAO-A inhibition of rizatriptan metabolism; the 5 mg dose is required when used with propranolol. Same triptan-class contraindications: coronary artery disease, vasospastic angina, uncontrolled hypertension, ischemic stroke history, hemiplegic or basilar migraine<ref name="maxalt-label" />.
	~~\| pharmacokinetics~~ =
	~~\| pharmacodynamics~~ =
	\| ~~indications~~ =
	\| ~~dosing~~ =
	\| ~~effects =~~
	\| ~~interactions~~ = <~~pharmaInteractions~~/>
	~~\| pregnancy_details =~~
	~~\| monitoring =~~
	~~\| counseling =~~
	~~\| anecdotes =~~
	~~\| seealso =~~
	~~\| references~~ =
	}}		}}

			== References ==
			<references />

	[[Category:~~Antimigraine agents~~]]		[[Category:Triptans]]
	[[Category:~~Triptans (5-HT1B/1D Agonists)~~]]		[[Category:Antimigraine medicines]]
	[[Category:Analgesics]]		[[Category:Analgesics]]

MDElliottMD: Category taxonomy ship: retag Migraine Medicines -> Antimigraine agents

2026-05-22T00:37:24Z

Category taxonomy ship: retag Migraine Medicines -> Antimigraine agents

← Older revision		Revision as of 00:37, 22 May 2026
Line 32:		Line 32:


	[[Category:~~Migraine Medicines~~]]		[[Category:Antimigraine agents]]
	[[Category:Triptans (5-HT1B/1D Agonists)]]		[[Category:Triptans (5-HT1B/1D Agonists)]]
	[[Category:Analgesics]]		[[Category:Analgesics]]

MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines

2026-05-14T15:07:07Z

Assign pharmacological categories from List_of_CNS-active_medicines

← Older revision		Revision as of 15:07, 14 May 2026
Line 31:		Line 31:
	}}		}}


			[[Category:Migraine Medicines]]
			[[Category:Triptans (5-HT1B/1D Agonists)]]
	[[Category:Analgesics]]		[[Category:Analgesics]]

MDElliottMD: Pharmacopedia: add

2026-05-14T03:31:08Z

Pharmacopedia: add <pharmaInteractions/>

← Older revision		Revision as of 03:31, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	\| interactions =		\| interactions = <pharmaInteractions/>
	\| pregnancy_details =		\| pregnancy_details =
	\| monitoring =		\| monitoring =

MDElliottMD: Pharmacopedia: remove contraindications parameter

2026-05-14T02:40:49Z

Pharmacopedia: remove contraindications parameter

← Older revision		Revision as of 02:40, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	~~\| contraindications =~~
	\| interactions =		\| interactions =
	\| pregnancy_details =		\| pregnancy_details =

MDElliottMD: Added empty fda_max parameter to MedTemplate call

2026-05-13T02:32:57Z

Added empty fda_max parameter to MedTemplate call

← Older revision		Revision as of 02:32, 13 May 2026
Line 8:		Line 8:
	\| starting_dose =		\| starting_dose =
	\| preparations =		\| preparations =
			\| fda_max =
	\| routes =		\| routes =
	\| onset =		\| onset =
Line 32:		Line 33:

	[[Category:Analgesics]]		[[Category:Analgesics]]

MDElliottMD: Expand stub to full MedTemplate parameter set

2026-05-13T01:00:00Z

Expand stub to full MedTemplate parameter set

@@ Line 1: / Line 1: @@
 {{MedTemplate
-| generic           = Rizatriptan
+| generic            = Rizatriptan
-| brand             = Maxalt
+| brand              = Maxalt
-| classes           = Triptan, Migraine medicine
+| structure          =
-| mechanism         = 5-HT1B/1D agonist
+| classes            = Triptan, Migraine medicine
 }}
 [[Category:Analgesics]]

MDElliottMD: Auto-created stub

2026-05-13T00:00:00Z

Auto-created stub

New page

{{MedTemplate
| generic = Rizatriptan
| brand = Maxalt
| classes = Triptan, Migraine medicine
| mechanism = 5-HT1B/1D agonist
}}
[[Category:Analgesics]]